A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers.

ABSTRACT:

Lessons learned

Disease control with signals of response were demonstrated, which should lead to future validating clinical trials using checkpoint inhibitors in this underserved rare malignancy population. Although the study of single types of rare cancers is practically challenging, clinical trial designs that aggregate such patients into cohorts treated similarly are feasible, even in the community setting.

Background

Patients with rare cancers are an underserved population with limited access to clinical trials aside from phase I trials in the refractory setting. Treatment of these patients is often based on collections of anecdotes and small denominator review articles. Despite broad evidence of efficacy of combined immune checkpoint blockade across multiple tumor types

SUBMITTER: Edenfield WJ 

PROVIDER: S-EPMC8417875 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature